Table of Contents

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

4. Impact Analysis

4.1 COVID-19 Impact Analysis

4.2 Impact of Ukraine- Russia war

4.3 Impact of ongoing Recession

4.3.1 Introduction

4.3.2 Impact on major economies

4.3.2.1 US

4.3.2.2 Canada

4.3.2.3 Germany

4.3.2.4 France

4.3.2.5 United Kingdom

4.3.2.6 China

4.3.2.7 Japan

4.3.2.8 South Korea

4.3.2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7.  PEST Analysis

8. Prostate health market Segmentation, By Disease Indication

8.1 Prostate Cancer

8.1.2 AR Directed Therapies

8.1.3 Hormone ADT

8.1.4 Cytotoxic Agents

8.1.5 PARP Inhibitors

8.2 Benign Prostate Hyperplasia

8.2.1 Alpha Blockers

8.2.2 5 Alpha Reductase

8.3 Prostatitis

8.3.1 Prescription

8.3.2 Over the counter

9. Regional Analysis

9.1 Introduction

9.2 North America

9.2.1 USA

9.2.2 Canada

9.2.3 Mexico

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Italy

9.3.5 Spain

9.3.6 The Netherlands

9.3.7 Rest of Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 South Korea

9.4.3 China

9.4.4 India

9.4.5 Australia

9.4.6 Rest of Asia-Pacific

9.5 The Middle East & Africa

9.5.1 Israel

9.5.2 UAE

9.5.3 South Africa

9.5.4 Rest

9.6 Latin America

9.6.1 Brazil

9.6.2 Argentina

9.6.3 Rest of Latin America

10.Company Profiles

10.1 Astellas Pharma

10.1.1 Financial

10.1.2 Products/ Services Offered

10.1.3 SWOT Analysis

10.1.4 The SNS view

10.2 Eli lilly and Company

10.3 Glaxo smithkline

10.4 Abbott Laboratories,

10.5 Abbvie

10.6 JOHNSON & JOHNSON SERVICES, INC.

10.7 AstraZeneca

10.8 Merck

10.9 SANOFI

10.10 Pfizer, inc.

11. Competitive Landscape

11.1 Competitive Benchmarking

11.2 Market Share Analysis

11.3 Recent Developments

12. Conclusion